Cargando…
In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product.
The c-erbB-2 product is thought to be a unique and useful target for antibody therapy of cancers overexpressing the c-erbB-2 gene. In vitro and in vivo anti-tumour effects of a humanised antibody against the extracellular domain of the c-erbB-2 gene product, rhu4D5, were examined. Rhu4D5 was less ef...
Autores principales: | Tokuda, Y., Ohnishi, Y., Shimamura, K., Iwasawa, M., Yoshimura, M., Ueyama, Y., Tamaoki, N., Tajima, T., Mitomi, T. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074476/ https://www.ncbi.nlm.nih.gov/pubmed/8645580 |
Ejemplares similares
-
Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal antibody.
por: Ohnishi, Y., et al.
Publicado: (1995) -
A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016) -
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth.
por: Harwerth, I. M., et al.
Publicado: (1993) -
Autonomous production of granulocyte-colony stimulating factor in tumour xenografts associated with leukocytosis.
por: Katoh, Y., et al.
Publicado: (1993) -
In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
por: Blumenthal, R D, et al.
Publicado: (2008)